A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK Inhibition
Phase 1 other active
Quick answer
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK Inhibition for Solid Tumors is a Phase 1 program (other) at Pasithea Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pasithea Therapeutics
- Indication
- Solid Tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active